For those at-risk patients who are young children, it is important to select safe and effective approaches to sedation. Dexmedetomidine and ketamine are two sedatives that are commonly used in children for procedural sedation, but they have some disadvantages when they are used alone. Dexmedetomidine-induced sleep is similar to natural sleep; patients may be awakened by external stimuli, causing sedation failure. Furthermore, the sedation effects of dexmedetomidine are concentration-dependent, and the decrease in heart rate caused by dexmedetomidine is also dose-dependent; therefore, increasing the dose of dexmedetomidine may be accompanied by decreased heart rate. 1 Intranasal ketamine sedation is fast acting in children, but ketamine may lead to high blood pressure, tachycardia, and irritability. 2 At our clinical sedation center, we administered dexmedetomidine combined with ketamine intranasally for sedation during transthoracic echocardiography in infants and young children since 2015. In this study, we retrospectively analyzed the clinical data of the infants and young children, and our primary purpose was to evaluate the sedative effects and safety of this two-drug combination;
the secondary purpose was to analyze risk factors for sedation failure during transthoracic echocardiography. 
| DATA AND METHODS

| Data collection
| Sedation method
The patients followed the fasting time guidelines according to the The certified nurses administered the sedative, monitored the patient, and recorded the relevant data in the sedation room. Several trained nurses were responsible for preparing the sedation medicine according to the weight of every patient. Dexmedetomidine (100 μg/ mL) and ketamine (50 mg/mL) were independently prepared using a 1-mL injector without dilution. All of the patients received sedation lying down in the arms of their parents, and nasal secretions were cleaned before intranasal sedation. To administer sedation, the patient was maintained in a semi-recumbent position with his/her head tilted slightly backward. Dexmedetomidine (2 μg/kg; 100 μg/mL) and ketamine (1 mg/kg; 50 mg/mL) were dripped into the nostrils individually using a 1-mL injector without a syringe needle, and the nose wings were gently massaged to promote absorption. If the drug did not drop into the nostrils completely during the sedation, the nurse would request instructions from the anesthetists and record the information on the sedation record; under this scenario, the child was subsequently excluded from the study. Once a satisfactory sedation effect was achieved, the patient was sent to the ultrasound exam room. After the exam, the patient was sent back to the sedation center to recover and was discharged or sent back to the ward after recovery.
What is already known
• Sedation is often required for young children during transthoracic echocardiography. Dexmedetomidine and ketamine are two sedatives that are commonly used in children for procedural sedation, but they have some disadvantages when they are used alone.
What this article adds
• Intranasal dexmedetomidine combined with ketamine is associated with acceptable safety and effectiveness for young children during transthoracic echocardiography.
The independent risk factors for sedation failure are cyanotic heart disease, history of sedation failure, history of congenital heart disease surgery, and fever.
Successful sedation was defined as an achieved sedation level of ≤3 on the observer assessment of alertness/sedation scale (mOAAS) 3 until the end of the exam, after initial intranasal dosing with dexmedetomidine (2 μg/kg) and ketamine (1 mg/kg). Sedation failure was defined as a mOAAS score >3 at 40 min after sedation, or patients awakening before the procedure was accomplished after initial intranasal dosing. Among cases of sedation failure, the patients were sent back to the sedation center for remedies including additional intranasal sedation (50% of the initial dose) or inhalation of 2-3% sevoflurane until the desired sedation effects were achieved. The time for sedation to take effect was defined as the time from the completion of intranasal administration to the time when the mOAAS score was ≤3. The recovery time was defined as the time from completion of exam to the time when the mOAAS score was ≥4. There was an awakening standard in our postsedation care unit.
According to this standard, if the patient did not recover within 30 min after the exam, the parents were instructed to whisper or pat the patient's shoulders and arms. If the patient still failed to recover as anticipated, a towel at room temperature was placed on the patient's face to stimulate recovery. All parents were taught to help the patients awaken once the exam was finished. The patients were considered appropriate for discharge (or returned to the ward) after they achieved our discharge criteria (Supplementary Figure S1) and maintained this level for at least 20 min. This is in accordance with the American Academy of Pediatrics and American Academy of Pediatric Dentistry. 4 Inpatients continued to be monitored after they returned to the ward. 4 A part of the patients might fall asleep again after they left our clinical sedation center, but those patients were easily arousable and protective reflexes were intact, it was not necessary to keep them alert all the time. Only if the patients needed to eat food, their parents were taught to awaken them.
We collected the various adverse reactions and divided them into two categories. The minor adverse reactions included (i) desaturation to <90% SpO 2 (for cyanotic congenital heart diseases, desaturation to <10% of the baseline value) for more than 10 s, with the need for airway interventions including the following: (i) repositioning, suctioning, and supplemental oxygen, (ii) prolonged recovery time, more than 2 h sleeping after the end of the procedure, (iii) continued crying or agitation after awakening for more than 30 min, (iv) nausea, without the need for intervention, and (v) somnolence, which is too sleepy to move or eat food. The severe adverse reactions included (i) desaturation to <90% SpO 2 (for cyanotic congenital heart diseases, desaturation to <10% of the baseline value) for more than 10 s, which could not be hypotension with blood pressure <5th percentile for age or 20% below baseline; (iv) arrhythmia, including bradycardia defined as heart rate below the 5th percentile for age; (v) allergic reaction; (vi) pulmonary aspiration; (vii) nausea or emesis requiring drug therapy.
The criteria were confirmed before the initiation of the study. There was a follow-up telephone call the next morning after the patients left our clinic sedation center to collect information on the delayed adverse reactions. Although we continued to contact the patients for 12 h on the day after the sedation, the percentage that we were able to contact was approximately 91%. was determined to screen these variables, and the screened variables were then incorporated into a stepwise logistic regression analysis.
T A B L E 1 Patients's demographics and diseases
No. (%)/median (interquartile range).
Age ( 
| General information
From May 2016 to August 2017, a total of 2352 sedations were performed, and 2304 patients who met the inclusion criteria were included in this study. Demographic features of the studied population and the diseases among the 2304 patients are shown in Table 1 . The vital signs of the patient condition at various time points are shown in Table 2 .
| Sedation efficacy
The sedation efficacy was judged by the sedation success rate, which was defined as a mOAAS score of ≤3 until the end of the exam after initial intranasal dosing with dexmedetomidine (2 μg/kg) and ketamine (1 mg/kg). In this study, the sedation success rate was 96.0% (2212/2304); only 92 patients required remedies after initial sedation failure and then they finished the exam (Figure 1 ; Sedation results).
Intranasal sedation with the combination of dexmedetomidine and ketamine took effect within 15. 
| Adverse reactions
All patients underwent the transthoracic echocardiography exam, and no severe adverse reactions were observed in this study ( 
| Analysis of sedation failure:
A total of 92 patients required remedies after initial sedation failure.
The univariate analysis of the factors contributing to sedation failure revealed that the incidences of cyanotic congenital heart disease, history of congenital heart disease surgery, history of past sedation failure, fever, and nasal secretions were significantly higher in patients whose sedation failed (Table 4) . No significant differences were observed with respect to gender, age, weight, nasal congestion, mental retardation, or sleep interval of <2 h between the patients whose sedations failed and those whose sedations succeeded. The significant (P < 0.05) variables of sedation failure were brought into the collinearity analysis. To avoid a collinearity issue, the variance inflation factor (VIF) was calculated to screen the variables, and then the screened variables were incorporated into the stepwise logistic regression analysis. The stepwise logistic regression analysis indicated that cyanotic heart disease, history of sedation failure, history of congenital heart disease surgery, and fever were independent risk factors for sedation failure (Table 5 ).
| DISCUSSION
Echocardiography is the primary assessment method for congenital or acquired heart disease in children. 6 To obtain clear ultrasound or ASA grades of III to IV. As a result, the risks will be increased during sedation. To ensure safe and effective sedation, a favorable sedation setting, ready-to-use rescue equipment, a professional sedation team, and the presedation assessment are essential, and a professional presedation assessment can help to prevent most adverse reactions. ; the bioavailability is as high as 82%, and no injury on the nasal nerves has been reported. 11, 12 However, there are some disadvantages of dexmedetomidine when it is used alone. First, the sedative effects of dexmedetomidine are concentration-dependent. When the plasma concentration of dexmedetomidine is between 0.2 and 0.3 ng/mL, the patients may be of arousable sedation. When the plasma concentration is above 1.9 ng/mL, the patients will be in deep sedation and difficult to arouse. 13 Previous studies found that the decrease in heart rate was also dose-dependent. 14 Milleret et al 15 intranasally administered dexmedetomidine (2 μg/kg and 3 μg/kg) to children during echocardiography, and 27% and 26% of the children in each group, respectively, experienced low heart rates (<80 bpm in 14% and 12% of the patients, respectively). Therefore, increasing the dose of dexmedetomidine may be accompanied by decreasing the heart rate. Second, dexmedetomidine-induced sleep is similar to natural sleep 16 ; thus, even with high-dose intranasal dexmedetomidine, patients may be easily awakened by external stimuli, which can cause sedation failure. Hence, it may be more effective to combine dexmedetomidine with another drug to compensate for the disadvantages of dexmedetomidine sedation rather than to simply increase the dose of dexmedetomidine.
Ketamine is a phencyclidine derivative with sedative and analgesic effects. 17 Studies have demonstrated that intranasal ketamine sedation is safe and fast-acting in children; sedation takes effect after approximately 5-10 min, and the plasma concentration peaks in 20 min, with no significant respiratory depression and no injury on the nerve in the nose. 18, 19 Ketamine does not release histamines and will not cause nasal sensitivity or nasal congestion. 20 Furthermore, ketamine leads to high blood pressure, tachycardia, and high cardiac output and therefore is often used in patients with hypovolemia or haemodynamic disorders. In our hospital, we used a combination of intranasal dexmedetomidine and ketamine under the hypothesis that ketamine would prevent dexmedetomidine-related bradycardia and give a more stable and effective sedation. Meanwhile, dexmedetomidine may prevent ketamine-related disadvantages, such as high blood pressure, tachycardia, and irritability. [21] [22] [23] This study demonstrated that intranasal sedation with a combination of dexmedetomidine and ketamine had an initial success rate of 96% with an acceptable safety profile, suggesting that this approach might be suitable for sedation in young children during echocardiography. The results derived from this study are notable due to the following factors: (i) a large sample size (2304 patients),
(ii) various types of diseases represented, including common and rare heart diseases, such as cyanotic and noncyanotic congenital heart disease, endocardia fibroelastosis, myocarditis, pericardial effusion, Kawasaki disease, and others, (iii) the study focused on young children, among them, 62.3% of the patients were less than 1 year old, and the youngest was only 13 days old.
Our data indicate that the independent risk factors for sedation failure were history of congenital heart disease surgery, history of sedation failure, cyanotic heart disease, and fever. Patients with a history of congenital heart disease surgery or a history of sedation failure usually had a history of high-dose, prolonged, or repeated sedation or analgesic drug use, and thereby resistance to the sedation drug may be the main cause of sedation failure. In this study, the echocardiogra- affect drug absorption and therefore result in sedation failure. In our center, nasal secretions were carefully cleaned before intranasal administration, so it might be why nasal secretions were not an independent risk factor for sedation failure in the study.
Previous studies 24, 25 found that sedation by intranasal dexmedetomidine at 3 μg/kg is associated with a 90% success rate in children undergoing echocardiography; meanwhile, mild to moderate bradycardia and hypotension were observed. In this study, 406 patients had a history of congenital heart disease surgery, 747 had a history of sedation or sedation failure, 157 had a fever, and they were all difficult to sedate from our research results. With a combination of intranasal dexmedetomidine and ketamine, the success rate of sedation was up to 96.0%, which is significantly higher than that of conventional sedation methods. 26 For difficult sedation cases, increasing the initial dose may improve the success rate of sedation, but further research is needed to validate the safety and efficacy.
There were some limitations of the study. First, this was a retrospective, observational study with no precise controls. Additionally, although all of the patients received intranasal sedation by the group of nurses who received professional training, the intranasal administration proficiency differed among individual nurses, and the duration of transthoracic echocardiography also varied between individual ultrasound doctors. We note that the exam time was relatively short. This could be due to a number of factors: (i) the number of patients requiring echocardiograms in China is large, therefore, resulting in very efficient processes for echocardiography (ii) good sedation and conditions for the examinations lead to idea study efficiency. Although the patients
were not awakened immediately after the exam, they might have undergone exams for longer time periods, but prolonged exam time still had a certain effect on the efficacy of the combination. The aforementioned limitations were unavoidable in this retrospective study and may have influenced the outcomes of the study. Further prospective controlled trials need to be designed to avoid these limitations.
| SUMMARY
Dexmedetomidine and ketamine are two sedatives commonly used in children. We administered these drugs together (intranasally) for sedation during transthoracic echocardiography in young children and obtained better results than either drug used as a sole agent.
This combination was successful even in difficult cases. Furthermore, the approach appeared to have an acceptable safety profile. This combination can help to meet the needs of transthoracic echocardiography exams and should be promoted in clinical practice. Further research is needed to investigate whether increasing the initial dose may improve the success rate of sedation.
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